Mayer Brown Advises AstraZeneca On Acquisition
The all-cash transaction, in which AstraZeneca would acquire all of MedImmune’s common stock for $58 per share, increases the pharmaceutical giant’s pipeline of biotechnology drugs by 45 projects to 163 projects.
“This acquisition represents a transformational step to deliver our biologics strategy sooner than anticipated,” said David Brennan, chief executive officer of AstraZeneca. “It creates a leading fully integrated biologics and vaccines...
To view the full article, register now.